Portal Hypertension Update: Comprehensive Summary
1. Main Clinical Topics Discussed
- Staging and prognosis of cirrhosis (compensated vs. decompensated)
- Role of elastography in risk stratification
- Management of esophageal and gastric varices (primary/secondary prophylaxis and acute hemorrhage)
- Baveno VII criteria and updated clinical algorithms
- Acute kidney injury in the context of cirrhosis (introduced at end of transcript)
2. Key Learning Points, Guidelines, and Recommendations
Cirrhosis Staging & Prognosis
- Cirrhosis is no longer a binary diagnosis; it is stratified by degree of fibrosis on elastography and presence of portal hypertension manifestations
- Compensated Advanced Chronic Liver Disease (cACLD) is the preferred terminology to reflect the continuum from advanced fibrosis (stage 3) to established cirrhosis (stage 4)
- Rate of transition from compensated to decompensated cirrhosis: 5–7% per year
- Median survival:
- Asymptomatic compensated cirrhosis: 12 years
- Symptomatic/decompensated cirrhosis: 2 years (without transplantation)
Elastography & Portal Hypertension Risk Stratification (Baveno VII)
- Liver stiffness measurement (LSM) is central to predicting Clinically Significant Portal Hypertension (CSPH), defined as hepatic venous pressure gradient (HVPG) ≥10 mmHg
- Low-risk criteria (endoscopy may be deferred):
- Platelet count >150,000 AND LSM <20 kPa
- High-risk threshold: LSM ≥20 kPa → assume advanced chronic liver disease; screen for varices
- Special populations:
- Primary Biliary Cholangitis (PBC): HVPG may underestimate portal hypertension severity due to pre-sinusoidal component and nodular regenerative hyperplasia → lower threshold for variceal screening
- NASH/Metabolic-associated liver disease: CSPH can occur even with HVPG <10 mmHg due to hepatic fat increasing portal pressure; varices may develop pre-cirrhotically
Variceal Screening & Surveillance Recommendations
- No varices detected + ongoing liver injury (e.g., NAFLD): Repeat endoscopy in 2 years
- No varices + cured hepatitis C: Endoscopy can be spaced further apart
- Small varices + ongoing liver injury: Repeat endoscopy in 1 year
- Small varices + cured hepatitis C: Repeat endoscopy every 2 years
Primary Prophylaxis of Esophageal Varices
- Large varices require prophylaxis; small varices can be observed
- Preferred agent: Carvedilol (alpha + non-selective beta blockade)
- Starting dose: 6.25 mg/day
- Target heart rate: 55–60 bpm, avoiding hypotension
- Beta-blocker reduction of HVPG confirmed to reduce variceal bleeding risk in alcoholic and viral hepatitis cirrhosis
- If beta-blockers are contraindicated or non-compliance is a concern: endoscopic variceal ligation (EVL) with annual surveillance endoscopy post-obliteration
Gastric Varices
- Classification relevant to bleeding risk:
- GOV1 (extension of esophageal varices to lesser curve): most likely to bleed; managed as esophageal varices with band ligation at EG junction
- GOV2 (extension toward fundus): less frequent bleeding but typically severe
- Isolated Gastric Varices (IGV): rare bleeding but characteristically severe
- Primary prophylaxis: Non-selective beta-blockers preferred; no established role for prophylactic endoscopic obliteration or TIPS/BRTO
- Acute gastric variceal hemorrhage management:
- Vasoactive drugs + antibiotics + volume resuscitation → urgent endoscopy
- Endosc